PharmiWeb.com - Global Pharma News & Resources
02-Oct-2019

IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV

Presentations include six-year data for the investigational regimen of cabotegravir and rilpivirine

London, 2 October 2019 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced it will present 20 abstracts from the company’s HIV research and development programs, as well as its community-based research initiatives, at the Infectious Disease Society of America (IDSA) IDWeek 2019, 2-6 October, in Washington, DC. The data highlight ViiV Healthcare’s commitment to not only develop innovative medicines that address the unmet need that still exists in HIV treatment, but also advance understanding of the emotional experiences and overall well-being of those who live with HIV.  

Kimberly Smith, M.D., Head of Research & Development at ViiV Healthcare, said: “People living with HIV are increasingly asking for a variety of treatment options to meet their evolving needs, and our data presentations at IDWeek 2019 show how ViiV Healthcare is delivering on this request. We are excited to be sharing data that describe the longer-term efficacy and safety of our 2-drug regimens and additional information relating to patient preferences for our long-acting regimen. We will also be presenting data that underscore the need to place additional attention on the role of mental health and well-being, especially as individuals age while living with HIV.” 

Data supporting 2-drug regimens (2DRs)

ViiV Healthcare is presenting data that describe the longer-term safety and efficacy of 2DRs, as well as patient adherence and preference with respect to these treatment regimens:

  • Six years of data (Week 312) from the LATTE study describes the longer-term efficacy and safety of the investigational 2DR of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine as a maintenance therapy in virologically suppressed patients.[i] These data underpin ongoing
    research efforts into this combination as a long-acting injectable regimen for adults living with HIV.
  • Pooled data from the ATLAS and FLAIR studies[ii] at Week 48 regarding injection timing of cabotegravir and rilpivirine. 
  • Patient-reported outcomes from additional studies will be presented on the long-acting regimen of cabotegravir and rilpivirine.[iii],[iv]
  • Results of subgroup efficacy analyses by baseline disease and demographic characteristics (secondary endpoint) from the pooled GEMINI 1 & 2 studies at Week 96 evaluating Dovato (dolutegravir plus lamivudine) in treatment-naïve adults with HIV-1.[v]
  • Week 148 data regarding treatment satisfaction and symptom burden before and after switching to Juluca (dolutegravir plus rilpivirine) from the SWORD 1 & 2 studies.[vi]

Data on the impact of HIV on the community

Recognising that achieving viral suppression is only one aspect of living with HIV, ViiV Healthcare will present data from innovative research initiatives that help to better understand the factors that contribute to quality of life in people living with HIV:

  • Findings from the Positive Perspectives survey, an international survey conducted by ViiV Healthcare, which evaluated the perspectives and attitudes of people living with HIV.[vii] 
  • The RISE study, a cross-sectional survey designed to obtain an up-to-date understanding of the unmet needs in virally suppressed people living with HIV in the US.[viii]

See the full Press Release on the ViiV website


[i] Margolis DA, Sutton KC, De Vente D, et al. Long term efficacy, safety and durability of CAB and RPV as two drug oral maintenance therapy – LATTE Week 312 results. Planned presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2019, 2-6 October, Washington, DC.

[ii] Teichner P, Cutrell A, D'Amico R, et al. Patient adherence to long-acting cabotegravir + rilpivirine through 48 weeks of maintenance therapy in the Phase 3 ATLAS and FLAIR studies. Planned presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2019, 2-6 October, Washington, DC.

[iii] Garris C, Heidenreich S, Arthurs E, et al. Perceptions of and preferences for oral or long-acting injectable antiretroviral treatment regimens in the United States and Canada. Planned presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2019, 2-6 October, Washington, DC.

[iv] Mantsios A, Murray M, Karver TS, et al. CARLA Women Women’s perspectives on and experiences with long-acting injectable anti-retroviral therapy in the United States and Spain: the potential role of gender in patient preferences. Planned presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2019, 2-6 October, Washington, DC.

[v] van Wyk J, Man C, Sievers J, et al. Durable efficacy of two-drug regimen (2dr) of dolutegravir (dtg) plus lamivudine (3tc) in antiretroviral treatment-naïve adults with hiv-1 infection at 96 weeks: subgroup analyses in the GEMINI studies. Planned presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2019, 2-6 October, Washington, DC.

[vi] Oglesby A, Angelis K, Punekar Y, et al. Juluca SWORD PROs data. Patient reported outcomes after switching to a 2-drug regimen of dolutegravir + rilpivirine:  Week 148 results from the SWORD-1 and SWORD-2 studies. Planned presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2019, 2-6 October, Washington, DC.

[vii] Young B, Marcotullio S, Punekar Y, et al. Experiences and emotional challenges of antiretroviral treatment (ART) - findings from the positive perspectives study. Planned presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2019, 2-6 October, Washington, DC.

[viii] Evans TM, Cutts KN, Swinburn P, et al. Mental health, quality of life, and accessibility to care among virally-suppressed people living with HIV in the United States. Planned presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2019, 2-6 October, Washington, DC.

Editor Details

Related Links

Last Updated: 02-Oct-2019